<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS/HYPOTHESIS: The <z:chebi fb="0" ids="39015">apolipoprotein</z:chebi> B (ApoB):<z:chebi fb="0" ids="39015">apolipoprotein</z:chebi> A (ApoA)-I ratio may be a better indicator of <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e>) risk in people with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> than traditional <z:chebi fb="23" ids="18059">lipid</z:chebi> risk markers (<z:chebi fb="1" ids="47774">LDL-cholesterol</z:chebi>, <z:chebi fb="4" ids="47775">HDL-cholesterol</z:chebi> and triacylglycerol), but whether the ApoB:ApoA-I ratio should be used to indicate <z:chebi fb="23" ids="18059">lipid</z:chebi>-lowering therapy is still debated </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: The <z:chebi fb="0" ids="5001">Fenofibrate</z:chebi> Intervention and Event Lowering in <z:mp ids='MP_0002055'>Diabetes</z:mp> (FIELD) study randomised 9,795 patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> to <z:chebi fb="0" ids="5001">fenofibrate</z:chebi> (200 mg daily) or placebo and followed them up for a median of 5 years </plain></SENT>
<SENT sid="2" pm="."><plain>We compared ApoB, ApoA-I, ApoAII and the ApoB:ApoA-I ratio with traditional <z:chebi fb="23" ids="18059">lipid</z:chebi> variables as predictors of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> risk </plain></SENT>
<SENT sid="3" pm="."><plain>We estimated the HR of the effect of 1 SD difference in baseline concentrations of <z:chebi fb="23" ids="18059">lipids</z:chebi>, <z:chebi fb="0" ids="39015">apolipoproteins</z:chebi> and respective ratios on the risk of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> events and also used receiver operating characteristic curve analysis </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: In the placebo group, the variables best predicting <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> events were non-<z:chebi fb="4" ids="47775">HDL-cholesterol</z:chebi>:<z:chebi fb="4" ids="47775">HDL-cholesterol</z:chebi>, total cholesterol:<z:chebi fb="4" ids="47775">HDL-cholesterol</z:chebi> (HR 1.21, p &lt; 0.001 for both), ApoB:ApoA-I (HR 1.20, p &lt; 0.001), <z:chebi fb="1" ids="47774">LDL-cholesterol</z:chebi>:<z:chebi fb="4" ids="47775">HDL-cholesterol</z:chebi> (HR 1.17, p &lt; 0.001), <z:chebi fb="4" ids="47775">HDL-cholesterol</z:chebi> (HR 0.84, p &lt; 0.001) and ApoA-I (HR 0.85, p &lt; 0.001) </plain></SENT>
<SENT sid="5" pm="."><plain>In the <z:chebi fb="0" ids="5001">fenofibrate</z:chebi> group, the first four predictors were very similar (but ApoB:ApoA-I was fourth), followed by non-<z:chebi fb="4" ids="47775">HDL-cholesterol</z:chebi> and ApoB </plain></SENT>
<SENT sid="6" pm="."><plain><z:chebi fb="23" ids="18059">Lipid</z:chebi> ratios and ApoB:ApoA-I performed better than any single <z:chebi fb="23" ids="18059">lipid</z:chebi> or <z:chebi fb="0" ids="39015">apolipoprotein</z:chebi> in predicting <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> risk </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSIONS/INTERPRETATION: In patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> in the FIELD study, traditional <z:chebi fb="23" ids="18059">lipid</z:chebi> ratios were as strong as the ApoB:ApoA-I ratio in predicting <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> risk </plain></SENT>
<SENT sid="8" pm="."><plain>The data provide little evidence for replacement of traditional <z:chebi fb="23" ids="18059">lipids</z:chebi> and their ratios with measures of ApoB, ApoA-I and their ratio </plain></SENT>
</text></document>